BACKGROUND: Patients suffering from morbid obesity (MO) have an increased cardiovascular morbidity and mortality. This increased cardiovascular burden is believed to be caused by a sub-inflammatory state through an increased secretion of monocyte chemoattractant protein-1 (MCP-1) by the adipose tissue, resulting in insulin resistance (IR) and type 2 diabetes mellitus (T2DM). YKL-40, which is elevated in inflammatory processes in T2DM and IR and in ruptured plaques, might as well be involved in the increased cardiovascular burden of MO patients. The present study aims to study the level of YKL-40 in MO patients before and after weight loss as well as to investigate the relationship between YKL-40, IR, MCP-1, and obesity. METHODS: We investigated YKL-40 levels in serum samples of both 17 morbidly obese patients before and after bariatric surgery and 17 healthy controls. YKL-40 levels were determined in serum samples by enzyme-linked immunosorbent assay. RESULTS: After a mean follow-up of 17.4 months and a mean weight loss of 40 kg through bariatric surgery, YKL-40 levels declined by 30.5% (p = 0.027). Multiple linear regression analysis revealed that only preoperative MCP-1 values remained independently and significantly (p = 0.001) associated with preoperative YKL-40 levels. Moreover, delta (change) homeostasis model assessment of insulin resistance (HOMA-IR) values remained independently and significantly (p = 0.002) associated with delta YKL-40 levels. CONCLUSIONS: We show for the first time that elevated levels of YKL-40 in MO patients decreased after massive weight loss via bariatric surgery. YKL-40 was correlated with HOMA-IR and fasting insulin levels, indicating a role in developing processes of IR and T2DM. The tight association of MCP-1 (plaque development) and YKL-40 (plaque rupture) points to a central role of both proteins, contributing to the increased cardiovascular mortality in MO patients.
BACKGROUND:Patients suffering from morbid obesity (MO) have an increased cardiovascular morbidity and mortality. This increased cardiovascular burden is believed to be caused by a sub-inflammatory state through an increased secretion of monocyte chemoattractant protein-1 (MCP-1) by the adipose tissue, resulting in insulin resistance (IR) and type 2 diabetes mellitus (T2DM). YKL-40, which is elevated in inflammatory processes in T2DM and IR and in ruptured plaques, might as well be involved in the increased cardiovascular burden of MO patients. The present study aims to study the level of YKL-40 in MO patients before and after weight loss as well as to investigate the relationship between YKL-40, IR, MCP-1, and obesity. METHODS: We investigated YKL-40 levels in serum samples of both 17 morbidly obesepatients before and after bariatric surgery and 17 healthy controls. YKL-40 levels were determined in serum samples by enzyme-linked immunosorbent assay. RESULTS: After a mean follow-up of 17.4 months and a mean weight loss of 40 kg through bariatric surgery, YKL-40 levels declined by 30.5% (p = 0.027). Multiple linear regression analysis revealed that only preoperative MCP-1 values remained independently and significantly (p = 0.001) associated with preoperative YKL-40 levels. Moreover, delta (change) homeostasis model assessment of insulin resistance (HOMA-IR) values remained independently and significantly (p = 0.002) associated with delta YKL-40 levels. CONCLUSIONS: We show for the first time that elevated levels of YKL-40 in MO patients decreased after massive weight loss via bariatric surgery. YKL-40 was correlated with HOMA-IR and fasting insulin levels, indicating a role in developing processes of IR and T2DM. The tight association of MCP-1 (plaque development) and YKL-40 (plaque rupture) points to a central role of both proteins, contributing to the increased cardiovascular mortality in MO patients.
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: R G Boot; T A van Achterberg; B E van Aken; G H Renkema; M J Jacobs; J M Aerts; C J de Vries Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: Anders R Nielsen; Christian Erikstrup; Julia S Johansen; Christian P Fischer; Peter Plomgaard; Rikke Krogh-Madsen; Sarah Taudorf; Birgitte Lindegaard; Bente K Pedersen Journal: Diabetes Date: 2008-07-23 Impact factor: 9.461
Authors: Naja Dam Mygind; Marina J Harutyunyan; Anders Bruun Mathiasen; Rasmus S Ripa; Jens Jacob Thune; Jens Peter Gøtze; Julia S Johansen; Jens Kastrup Journal: Inflamm Res Date: 2010-10-23 Impact factor: 4.575
Authors: Berit B Aam; Ellinor B Heggset; Anne Line Norberg; Morten Sørlie; Kjell M Vårum; Vincent G H Eijsink Journal: Mar Drugs Date: 2010-04-27 Impact factor: 5.118
Authors: Jingjing Zhu; Tracy A O'Mara; Duo Liu; Veronica Wendy Setiawan; Dylan Glubb; Amanda B Spurdle; Peter A Fasching; Diether Lambrechts; Daniel Buchanan; Pik Fang Kho; Linda S Cook; Christine Friedenreich; James V Lacey; Chu Chen; Nicolas Wentzensen; Immaculata De Vivo; Yan Sun; Jirong Long; Mengmeng Du; Xiao-Ou Shu; Wei Zheng; Lang Wu; Herbert Yu Journal: Cancers (Basel) Date: 2021-04-26 Impact factor: 6.639